Returns On Capital Signal Tricky Times Ahead For Guangzhou LBP Medicine Science & Technology (SHSE:688393)

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. However, after investigating Guangzhou LBP Medicine Science & Technology (SHSE:688393), we don't think it's current trends fit the mold of a multi-bagger.

Return On Capital Employed (ROCE): What Is It?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Guangzhou LBP Medicine Science & Technology, this is the formula:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.0086 = CN¥11m ÷ (CN¥1.4b - CN¥74m) (Based on the trailing twelve months to December 2024).

Thus, Guangzhou LBP Medicine Science & Technology has an ROCE of 0.9%. In absolute terms, that's a low return and it also under-performs the Medical Equipment industry average of 6.8%.

See our latest analysis for Guangzhou LBP Medicine Science & Technology

While the past is not representative of the future, it can be helpful to know how a company has performed historically, which is why we have this chart above. If you'd like to look at how Guangzhou LBP Medicine Science & Technology has performed in the past in other metrics, you can view this free graph of Guangzhou LBP Medicine Science & Technology's past earnings, revenue and cash flow.

So How Is Guangzhou LBP Medicine Science & Technology's ROCE Trending?

On the surface, the trend of ROCE at Guangzhou LBP Medicine Science & Technology doesn't inspire confidence. To be more specific, ROCE has fallen from 18% over the last five years. Meanwhile, the business is utilizing more capital but this hasn't moved the needle much in terms of sales in the past 12 months, so this could reflect longer term investments. It's worth keeping an eye on the company's earnings from here on to see if these investments do end up contributing to the bottom line.

The Bottom Line

To conclude, we've found that Guangzhou LBP Medicine Science & Technology is reinvesting in the business, but returns have been falling. Although the market must be expecting these trends to improve because the stock has gained 27% over the last three years. Ultimately, if the underlying trends persist, we wouldn't hold our breath on it being a multi-bagger going forward.

Guangzhou LBP Medicine Science & Technology does come with some risks though, we found 3 warning signs in our investment analysis, and 2 of those are a bit concerning...

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.